New lotion could ease rare skin disorder

NCT ID NCT05521438

Ongoing Disease control Sponsor: Quoin Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a lotion called QRX003 in 30 people with Netherton Syndrome, a rare genetic skin condition. The lotion contains a drug that blocks certain enzymes thought to cause skin problems. Researchers are checking if it reduces redness, scaling, and itching compared to a placebo lotion.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QRX003 lotion (a serine protease inhibitor)
What this could lead to: If it works, this could provide a topical treatment to control skin symptoms like redness, scaling, and itching in Netherton Syndrome.
What could go wrong: This is an early-to-mid stage trial with only 30 people, so results may not apply to everyone. The lotion may cause skin reactions or not work better than a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NETHERTON SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Netherton syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NETHERTON SYNDROME

Contacts and locations

Locations

Site #1

San Diego, California, 92123, United States
Site #2

San Antonio, Texas, 72218, United States
Site #3

Charleston, South Carolina, 29425, United States
Site #4

Indianapolis, Indiana, 46250, United States
Site #5

Quincy, Massachusetts, 02169, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.